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Abstract
Aims: The TTM2-trial is a multi-centre randomised clinical trial where targeted temperature management (TTM) at 33 C will be compared with
normothermia and early treatment of fever (37.8 C) after Out-of-Hospital Cardiac Arrest (OHCA). This paper presents the design and rationale of the
TTM2-trial follow-up, where information on secondary and exploratory outcomes will be collected. We also present the explorative outcome analyses
which will focus on neurocognitive function and societal participation in OHCA-survivors.
Methods: Blinded outcome-assessors will perform follow-up at 30-days after the OHCA with a telephone interview, including the modified Rankin Scale
(mRS) and the Glasgow Outcome Scale Extended (GOSE). Face-to-face meetings will be performed at 6 and 24-months, and include reports on
outcome from several sources of information: clinician-reported: mRS, GOSE; patient-reported: EuroQol-5 Dimensions-5 Level responses version (EQ-
5D-5L), Life satisfaction, Two Simple Questions; observer-reported: Informant Questionnaire on Cognitive Decline in the Elderly-Cardiac Arrest version
(IQCODE-CA) and neurocognitive performance measures: Montreal Cognitive Assessment, (MoCA), Symbol Digit Modalities Test (SDMT).
Exploratory analyses will be performed with an emphasis on brain injury in the survivors, where the two intervention groups will be compared for potential
differences in neuro-cognitive function (MoCA, SDMT) and societal participation (GOSE). Strategies to increase inter-rater reliability and decrease
missing data are described.
Discussion: The TTM2-trial follow-up is a pragmatic yet detailed pre-planned and standardised assessment of patient’s outcome designed to ensure
data-quality, decrease missing data and provide optimal conditions to investigate clinically relevant effects of TTM, including OHCA-survivors’
neurocognitive function and societal participation.
Keywords: Cardiac arrest, Treatment outcome, Cognitive function, Patient Reported Outcome Measures, Quality of life
Introduction
In countries where withdrawal of life-sustaining therapies (WLST) is
routinely employed, only 510% of patients discharged alive from
hospital after out-of-hospital cardiac arrest (OHCA) experience a poor
neurological outcome when crude outcome scales are used.1 With
more detailed outcome evaluation, approximately half of OHCA-
survivors show long-term neurocognitive impairment, especially in the
domains of memory, attention/processing speed and executive
functions.2,3 Neurocognitive impairment in OHCA-survivors is asso-
ciated with lower levels of societal participation and less return-to-
work.4
The Targeted Hypothermia versus Targeted Normothermia
after OHCA (TTM2) trial was designed to assess whether
targeted temperature management (TTM) at 33 C is superior
to early treatment of fever (37.8 C).5 The primary outcome
of the TTM2-trial is all-cause mortality at six months after
randomisation. Secondary outcomes include poor functional
outcome and patient-reported health related quality-of-
life (HRQoL). The explorative analyses of the TTM2-trial are
specified to provide increased granularity in the estimation of
brain dysfunction for the comparison of the two intervention
regimens.
The aims of this manuscript are:
1 To provide detailed information on the design of the TTM2-
trial follow-up, in line with the SPIRIT-PRO Extension
guidelines.6
2 To describe the exploratory analyses of the TTM2-trial that focus
on the survivors outcomes of neurocognitive function and societal
participation.
Methods
Time-points
The main time-point for primary, secondary and exploratory outcomes
is six months after randomisation. At this time-point most neurological
recovery has occured.79 Furthermore, return-to-work typically occurs
around 4-months post-OHCA.10Consequently most participants will,at
least to some extent, be reintegrated into their normal lives at 6-months.
In the previous TTM-trial,1 the six month time-point for follow-up was
feasible in terms of patient inclusion, with 92% of survivors participat-
ing.11 In the TTM2-trialadditional time-points at30-days and 24-months
post-randomisation will be used to explore the time-course of recovery
in survivors.
Population
Established from the a priori power calculation for the primary
outcome,5 the TTM2-trial will include 1900 unconscious OHCA-
patients, 18 years of age, with a presumed cardiac or
unknown cause of arrest. Detailed inclusion and exclusion criteria,
routines for neurological prognostication and criteria for WLST have
been published.5 Efforts to minimise avoidable missing data is an
important part of the study-design, and includes user-friendly tests,
training sessions, regular monitoring, and remote support of each
participating site by a central coordinator.
Setting
Participants in the TTM2-trial are recruited at multiple sites in several
countries (Table 1). The 30-day follow-up is a telephone interview. The
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Table 1 – .
Outcome Outcome
assessment
Scoring Time-point Source of information Translations*
30-days 6-months 24-months PRO ObsRO ClinRO Performance test
Functional outcome related
to neurological function
mRS Range 06       Yesa
0 =no symptoms Available at www.modifie-
drankin.com
6=dead
Poor outcome mRS 46
Functional outcome related
to neurological function,
with a focus on societal
participation
GOSE Range 18       Yesb
1 =dead
0=upper level of good recovery
Poor outcome GOSE 14
Generic health EQ-5D-5L Dimension scores; range 15    Yes
1=No problems By the Euroqol group
5=Extreme problems
Scores 2 indicates problems
Index scores; range 0.285 to
1.00
<0.00 =health status worse
than being dead
VAS scores: range 0100
Scores <70 represent poor
health
Global cognitive function MoCA Scores 030    Yes
Scores <26 indicates cognitive
impairment
Available at mocatest.org
2518 mild impairment
710 moderate impairment
<10 severe impairment
Mental processing speed SDMT Number of correct symbols 0
110
   Not language specific
Scores 11.5 standard devia-
tions below the mean of a
specific age andeducation level
are considered suggestive of
cerebral dysfunction.
Scores 2 standard deviations
below the mean of a specific
age and education level are
considered very low.
Cognitive problems in daily
life
IQCODE-CA Total score ranges from 1.0 to
5.0.
   Yesc
1
0
6
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Table 1 (continued)
Outcome Outcome
assessment
Scoring Time-point Source of information Translations*
30-days 6-months 24-months PRO ObsRO ClinRO Performance test
Scores at or above 3.04 was
found to be an optimal cut-off to
indicate cognitive problems af-
ter cardiac arrest
Original version available at
www.rsph.anu.edu.au/re-
search/tools-resources/in-
formant-questionnaire-cog-
nitive-decline-elderly.
Mental recovery/
dependency
TSQ Yes to question 1a and Yes to
question 1b indicate new prob-
lems with dependency after
cardiac arrest
   Yes
No to question 2 indicate prob-
lems with mental recovery after
cardiac arrest
Translated by the TTM-trial
investigators.
Life satisfaction One question
on life satisfac-
tion from the
World Value
Survey
Score range from 0
(=completely dissatisfied) to 10
(=completely satisfied)
   Yes
National normative data
available
Provided from the www.
worldvaluessurvey.org/
wvs.jsp and by the secre-
tariat of the World Values
Survey Association (2017-
11-23)
Abbreviations: PRO=Patient ReportedOutcome;ObsRO=Observer ReportedOutcome;ClinRO=ClinicanReportedOutcome;mRS=modifiedRankinScale;GOSE=GlasgowOutcomeScaleExtended; EQ-5D-5L=EuroQol
health survey 5 Dimensions 5 Levels responses version; MoCA=Montreal Cognitive Assessment; SDMT=Symbol Digit Modalities Test; IQCODE-CA= Informant Questionnaire on Cognitive Decline in the Elderly, Cardiac
Arrest version; TSQ=Two Simple Questions.
* Participating countries in the TTM2-trial: Australia, Austria, Belgium (French and Flemish), Czech Republic, Denmark, France, Germany, Italy, New Zealand, Norway, Sweden, Switzerland (French, Italian, German), United
Kingdom and USA.
a mRS 9 Questions (mRS-9Q) was available in English and Danish. Remaining versions were translated for the TTM2-trial by the national investigators (accepted by dr Flint personal communication 2017-11-25).
b For the GOSE translated versions was shared from the CENTER-TBI project and further modified for cardiac arrest use for the TTM2-trial (approved by Professor Lindsay Wilson, personal communication 2017-01-24). The
modifications were translated by the TTM2-trial national investigators. The Danish version was translated specifically for the TTM2-trial.
c For IQCODE-CA a slight modification for cardiac arrest use was performed (approved by Professor Anthony Jorm, personal communication 2010-05-13) and translated for the TTM and/or TTM2-trial by the national
investigators.
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follow-ups at six and 24 months are performed as face-to-face
interviews in a clinical setting. Alternative follow-up strategies; such as
visiting the participant’s placeof residenceor interview by telephone are
used to avoid missing data. Since some tests are impossible to perform
by telephone, this approach is only used when no other options are
available. As a last resort, information may be provided by a proxy.
Procedures
Blinded outcome assessors e.g. occupational therapists, psycholo-
gists, physiotherapists, physicians or research nurses distribute the
assessment tools in a pre-specified order according to the follow-up
manual. The duration of the 6 and 24-months follow-up visit is
approximately 4060 min. For participants who are unable to speak
the local language, an authorised interpreter is used.
Efforts to increase inter-rater reliability include the use of
psychometrically sound measures, a written follow-up manual
(https://ttm2trial.org/documents) and a four hour training session
for outcome assessors. A central coordinator provide support during
the study and review the outcome data at regular intervals to check for
completeness and data-quality.
Outcome assessments
Instruments to assess secondary and exploratory outcomes (Table 1)
were chosen based on their ability to capture the outcomes of interest,
acceptable psychometric properties, and previous use in Cardiac
Arrest (CA) and brain injury. In addition, instruments should be
extensively translated and not too time consuming. The choice was
further informed by the recommendations for a Core Outcome Set
after Cardiac Arrest (COSCA) to allow for comparisons with other CA-
trials.12
Secondary outcome assessments
Modified Rankin Scale (mRS) is a clinician-reported ordinal rating
scale representing an overall view of functional outcome after a
neurological event or condition, previously used in a number of CA-
trials.12 It has seven categories, ranging from 6 = dead to 0 = no
symptoms; including both information on survival, limitations in basic
or instrumental daily activities, restrictions participating in normal
social roles and effects of physical, cognitive and emotional
symptoms. Substantial inter-rater variability was reported for the
mRS, when used by multiple raters and sites,13 but reliability improves
with a structured approach.13,14 In the TTM2-trial the mRS will be
based on a structured interview with nine questions (mRS-9Q), and a
web-based scoring tool (www.modifiedrankin.com).14 Information for
the mRS is collected from several reporters; the participant, observer
(e.g. relative or close friend) and the outcome-assessor.
EuroQol 5 Dimensions 5 Levels response version (EQ-5D-5L)15 is
a patient-reported generic-HRQoL questionnaire with five questions/
dimensions of health (mobility, self-care, usual activities, pain/
discomfort and anxiety/depression) together with a visual analogue
scale (VAS) of self-reported health (0100 = best health possible).15
Each dimension has five levels of scoring, from no problems (1) to
extreme problems (5) and is used to present a descriptive health
profile (scores 2 indicate problems),15 or converted to a single value
of health (EQ-5D-5L index). The EQ-5D-5L index facilitates statistical
analyses and can be used to calculate quality-adjusted life years
Table 2 – Overview of patient characteristics collected. Full information on different variables collected in the
TTM2 trial CRF is available at https://ttm2trial.org/documents.
During
hospital
stay
At 30 days
follow-up
At 6 months
follow-up
At 24 months
follow-up
Socio-demographical information including age, sex 
Resuscitation variables including scene of cardiac arrest, witnessed arrest, bystander CPR, first
monitored rhythm, use of active mechanical CPR, Time to ROSC, cause of the arrest etc.

Medical background data collected by Charlson comorbidity index, pre-arrest frailty score, pre-
arrest mRS score, and information on previous cardiac disease; PCI, CABG, known
cardiomyopathy, ICD, atrial fibrillation or flutter, hypertension with pharmacologic treatment

Days at ICU 
Days at hospital 
Native language other than the test language (yes/no)  
Difficulties that may interfere with the test results; non-correctable problems with hearing, vision,
speech, dyslexia, paresis, other (yes/no)
 
Memory problems prior to cardiac arrest (yes/no)  
Known neurological disease (yes/no)  
Education level based on an international standard classification of education by UNESCO 
Living situation (married/living as married/or living alone)  
Current place-of-stay   
Occupational status prior to cardiac arrest  
Current occupational status, and time-point for return-to-work  
Rehabilitation provided  
Cardiovascular risk by the Framingham coronary heart disease risk score(=age, gender,
smoker, total cholesterol, HDL cholesterol, systolic blood pressure, on medication for
hypertension, diabetes), BMI, HbA1C and frequency of physical activity
 
General physical function by the Timed Stands Test  
Abbreviations: CPR = Cardio Pulmonary Resuscitation, ROSC = Return of Spontaneous Circulation, mRS= modified Rankin Scale, PCI = Percutaneous Coronary
Intervention, CABG = Coronary Artery Bypass Grafting, ICD = Implantable Cardioverter Defibrillator, ICU= Intensive Care Unit, UNESCO = United Nations
Educational, Scientific and Cultural Organization, HDL= High Density Lipoprotein, BMI = Body Mass Index.
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(QALYs) in health-economic evaluations.15 The EQ-VAS is reported
separately. When a patient is unable to report their health (e.g. severe
neurological impairment/lack of awareness) proxy-completion is
allowed.
Exploratory outcome assessments
Glasgow Outcome Scale Extended (GOSE) is a clinician-reported
global outcome scale to describe functional outcome after brain
injury.16 GOSE is an extended version of the Glasgow Outcome Scale
(GOS), developed to decrease ceiling-effects and increase discrimi-
nation in the upper levels of recovery.17 GOSE has 8 categories
ranging from 1 = dead to 8 = upper level of good recovery, preferably
defined using a structured interview16,17 and information from several
sources.17 For TTM2 the structured GOSE interview was modified
from its original wording of “injury” to read “cardiac arrest”. In addition
to the total score, the structured interview includes descriptive
information regarding pre-arrest function, and the most important
factor for the outcome (brain injury or other). GOSE can be converted
to a simple GOS,16,17 which corresponds to the much used, but
criticized,12 Cerebral Performance Category (CPC)-scale.
Montreal Cognitive Assessment (MoCA)18 is a cognitive perfor-
mance-measure, reported to perform well for cognitive screening after
cardiac arrest (CA),19 and recommended in current guidelines.20 The
MoCA consists of 11 sub-tests of six cognitive domains; short-term
memory, attention, working memory, visuo-spatial ability, executive
function and language, all summed into a composite score of global
cognitive function (030 points, higher is better). Scores <26 indicate
cognitive impairment. Test-retest reliability for the MoCA is excellent
(0.92).18
Symbol Digit Modalities Test (SDMT)21 is a cognitive performance-
measure of mental processing speed and attention, considered as
one of the most sensitive tests to identify effects of brain injury,21 which
possibly also includes OHCA-specific cognitive impairment.2 The
combination of MoCA and SDMT increased the sensitivity of cognitive
screening.22 In TTM2 the oral version of the SDMT is used,21 and the
written version only employed in cases of speech or language
problems. Test-retest reliability of the SDMT is 0.76 for the oral
version.21
Life Satisfaction is reported by a single item from the World Values
Survey (www.worldvaluessurvey.org) used together with a VAS scale
(010 = completely satisfied). This question reflects the patients’
subjective overall satisfaction with life.
Informant Questionnaire on Cognitive Decline in the Elderly-
Cardiac Arrest version (IQCODE-CA)23,24 is an observer-reported
questionnaire to investigate change/decline of performance in
26 everyday activities related to cognitive function,23 modified to
better suit a CA context (IQCODE-CA).24,25 IQCODE-CA does not
involve participation from the patient, and information on outcome can
also be obtained for participants who do not speak the local language
or have severe cognitive impairment.
Two Simple Questions (TSQ) was developed to assess the
patient’s own perception of mental recovery and dependency in daily
activities after CA.25,26
Return-to-work is studied by collecting information on the patient’s
occupational status before the index hospitalization and at time of the
follow-up.
Clinical characteristics
Patient characteristics are obtained at several time-points (Table 2).
At both the 6 and 24-months follow-up objective information of the
participants’ general physical function and current cardiovascular risk
is collected. General physical function is measured by the Timed-
Stands Test (TST),27 assessing lower-limb function by recording the
time required for the participant to rise 10 times from a chair to a
standing position (shorter time = better).27 Cardiovascular risk is
assessed by the Framingham coronary heart disease risk score,28
Body Mass Index (BMI), HbA1C, and physical activity. Physical
activity is measured by two self-reported questions created for the
TTM2-trial (Table 3) based on recommendations for primary and
secondary cardiovascular prevention.29 These questions will be
validated in a TTM2 sub-study on physical activity (Clinicaltrials.gov
NCT03543332).
Table 3 – Questions for self-reported physical activity in the TTM2-trial.
Questions on physical activity
Question 1 (Q1) In the last week, how many days have you engaged in moderate physical activity for at least 30 min a day? (could be
performed in blocks that last for at least 10 min adding up to a total of 30 min or more)
Physical activity Note: Moderate activities means pursuits that requires to a moderate level of effort and noticeably increase in heart rate.
Examples includes a brisk walk, rigorous cleaning, washing windows, cleaning the car, carpentry, bicycling with light effort,
golf, swimming or similar. For more examples see Haskell et al. 2007. Circulation.
Question 2 (Q2) In the last week, how many days have you engaged in vigorous (intense) aerobic physical activities for at least
20 min (in one block)?
Physical training Note: Vigorous or intense aerobic physical pursuits are activities that lead to substantial increase in heart rate and rapid
breathing. Examples of activities at this level include jogging, running, walking very briskly, shovelling/digging, cycling with a
moderate effort/fast, swimming moderately/hard, tennis or similar. For more examples see Haskell et al. 20007. Circulation.
Categorization of physical activity
Physical activity below recommended levels for primary and secondary prevention Sedentary <5 on Q1
<3 on Q2
=less than 150 activity minutes in a week
Physical activity to a level recommended for primary prevention Physical activity 5 on Q1
OR
3 on Q2
Physical activity to a level recommended for primary, and secondary
prevention after coronary artery disease
Physical training 2 on Q1
AND
3 on Q2
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Statistical methods
The primary and secondary outcomes of the TTM2-trial will be
reported in the main paper.5 The exploratory outcomes presented
here will be reported separately focusing on the OHCA-survivors at six
months.
The comparisons of detailed outcomes for OHCA-survivors in the
two intervention groups will be restricted to global cognition (total
MoCA score, 030), mental processing speed/attention (SDMT raw
score, 0110) and societal participation (GOSE score, 18) to limit
problems with multiplicity. In the first analyses all participants will be
included to avoid survival bias. For MoCA and SDMT, deceased
participants will be assigned a score lower than the lowest possible for
survivors, and for all analyses (MoCA, SDMT, GOSE) the non-
parametric van Elteren test will be used, stratified by site.
The second analyses will include survivors only, and mixed effects
ordinal regression will be used for the GOSE, and mixed effects linear
regression models for the MoCA and SDMT. Analyses will be
performed adjusted for site (random intercept) and co-enrolment in
TAME cardiac arrest trial.5 As the balanced allocation by the
randomisation process may no longer be valid due to differences in
mortality, additional analyses will be performed including also
adjustment for age, sex, education, and pre-arrest clinical frailty
score (14 vs. 59). An alpha value of <0.05 will be used to indicate
statistically significant results without any further adjustment for
multiplicity due to the exploratory design. In addition to statistical
significance, effect measures will be reported.
Sensitivity analyses taking the distribution of missing data into
account will be considered.30
By using the survival rate assumed in the primary outcome5 we
estimate the sample size for the exploratory outcome analyses of the
survivors to be approximately 900. The estimated power will then be
99% for the MoCA assuming a minimal important difference (MID) of
2,31,32 and a standard deviation (SD) of 3 (based on data from patients
with mild cognitive impairment).32 For the SDMT the power will be 85%
using data from the TTM1-trial,2 and a Cohens d of 0.2 to represent a
MID. Power calculations for the MoCA and SDMT are based on
unadjusted linear regression.
Descriptions of MID for the GOSE are rare. For the similar
categorical scale mRS, small absolute differences as low as 1.1
1.5% have been suggested clinically relevant for the transition from
poor to good functional outcome,33 although differences of 510%
were also suggested.33 Using both thresholds, data from the TTM1-
trial and ordinal regression provided an OR = 1.2 for the lower MID
(1.5%) with a power of 32%, and a OR = 1.6. for the higher MID (5%)
with a power of 97%.
To facilitate interpretation of the results, categorical information of
each assessment (GOSE, MoCA, SDMT) will be presented descrip-
tively based on pre-specified cut-off values for the MoCA and age and
education adjusted z-scores for the SDMT. Descriptive information will
be presented stratified by the intervention groups, but without further
testing of statistical significance. The other outcomes (IQCODE-CA,
TSQ, Return-to-work and Life Satisfaction) will be presented to provide
supplementary information from a more general perspective on
outcome of OHCA-survivors only. Clinical data and patient character-
istics of importance to interpret the results will be reported.
For all analyses categorical values will be presented as both
numbers and percentages, and for the continuous values median
(IQR) and/or mean (SD).
The analyses of the 24-month outcome data will be reported
separately.
Discussion
This paper presents the design and rationale of the TTM2-trial follow-
up, where information on secondary and exploratory outcomes will be
collected. We also present the explorative outcome analyses which
will focus on neurocognitive function and societal participation in
OHCA-survivors. The TTM2 follow-up design complies with current
recommendations that resuscitation trials focusing on the quality-of-
survival should report neurological function and long-term outcomes
at 3-months post-arrest or later, and preferably include more detailed
neurocognitive testing and patient-reported HRQoL.12,34,35
A major strength of the TTM2-trial is the size of the trial and the
global distribution of participating sites. This will provide unique
information on outcome related to temperature control, but also
regarding outcome of OHCA-survivors in general. However, a
concern for large clinical trials is that multiple outcome-assessors
and sites may increase variability, decrease inter-rater reliability, and
potentially bias the results.36 A major focus of the TTM2 follow-up
design is therefore to use a well-defined structure for outcome-reports,
further supported by training and central feed-back. This approach is
expected to increase inter-rater reliability and provide more granularity
in the scoring within the good outcome categories by the mRS and the
GOSE, but may impair the comparisons with other studies using a less
detailed approach. Analyses where participants are dichotomized into
good or poor outcome, are still assumed to be comparable.
The mRS is currently the recommended measure for overall
functional outcome after CA.12 The mRS was designed to measure
outcome after stroke, with a large focus on mobility problems. The
GOSE was developed with a focus on the non-physical aspects of brain
injury and societal participation, but also includes a score that
corresponds to vegetative state.16 GOSE was suggested as a potential
outcome measure after CA,34 but it is currently used less than the mRS
and not recommended to be used alone.12 Our inclusion of both scales
will provide information that may inform future recommendations.
It is recommended to include the patient’s perspective on outcome
in resuscitation trials.12,34,35 There is currently no patient-reported
outcome measure (PROM) specifically designed for CA, but the EQ-
5D-5L has been suggested.12 EQ-5D is the most used PROM world-
wide, and also extensively used after CA.37 The popularity of the EQ-
5D is related to its brevity and ease of use, important features in a
sample at high risk of cognitive impairment, such as OHCA-survivors.
The updated version with 5 levels of responses (EQ-5D-5L) has
improved psychometric properties,15 but has not yet been tested in
OHCA-survivors.37 A high ceiling effect for the original EQ-5D-3 L
(46%) was reported also for CA-survivors, but it decreased (26%)
when proxy reports were included.38 This indicates that exclusion of
poor outcome survivors in OHCA-trials may bias the results by
overestimating outcome.37 The TTM2-trial will allow for proxy
completion of the EQ-5D-5L when necessary.12,37
Since neither functional outcome measures (mRS, GOSE) or
generic PROMs (EQ-5D-5L) provide detailed information on neuro-
cognitive function, it is recommended to add condition/function-
specific assessments.12 This may be especially important when
neuro-protective effects are investigated so that clinically important
information is not lost. Detailed neurocognitive testing is impractical in
a large international trial. We therefore chose two simple
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neurocognitive assessments (MoCA, SDMT) that are widely used and
recommended for cognitive screening after CA.20 Whether they are
sensitive enough will be further tested in a TTM2-sub-study using
more extensive neuropsychological tests (ClinicalTrials.gov
NCT03543371).
Cognitive performance measures in the TTM2-trial are combined
with subjective reports from the patientandthe observerperspective, as
recommended by the US Food and Drug Administration (FDA).39
Observer and patient-reports may be a sensitive approach to identify
mild cognitivedecline, although these reports may also be influenced by
problems unrelated to brain injury, such assymptoms ofdepression.9,24
The subjective reports of the TTM2-trial will therefore be reported as
descriptive information, without the intention to analyse causality.
The optimal time-point to evaluate OHCA-survivors’ final outcome
is unknown. With increasing time more participants may be lost to
follow-up and other factors, unrelated to the initial arrest, may
influence results. The first outcome-report in the TTM2-trial at 30-days
post-arrest is in line with the COSCA-recommendation,12 but this is
too early to reflect the participants’ long-term outcome and return to a
normal life cannot be assessed. Also the second time-point suggested
by the COSCA,12 at 90-days, is assumed too early12 and will not be
used in the TTM2-trial. The COSCA-recommendation further support
HRQoL assessments at 6-months and/or 1-year.12 In the TTM2-trial
all main analyses will be performed at 6-months after the CA based on
neurological recovery and societal integration.7,8,10 A few previous
smaller studies report that, at a group level, neurocognitive outcome
after CA did not change between 3- and 12-months,79 but at an
individual level remained stable, improved or declined. The 24-months
follow-up will offer novel information on long-term prognosis of OHCA-
survivors and complement the main follow-up.
The progressive cognitive decline seen in some OHCA-survivors
may be associated with their cardiovascular burden. A high
Framingham cardiovascular risk score is associated to increased
cognitive decline40 in the same domains typically impaired after CA.2,3
In line with this reasoning we previously reported similar levels of
cognitive impairment among OHCA-survivors and myocardial infarc-
tion controls.2 To explore the potential association between long-term
cognitive impairment and cardiovascular risk-factors in OHCA-
survivors is important, both for the design of follow-up programs,
but also for the interpretation of responsiveness regarding effects of a
neuro-protective intervention in the acute-phase.
Conclusion
This paper describes the choice of outcome measures and follow-up
design of the TTM2-trial, a large international multi-centre research
collaboration. Outcome assessments with established psychometric
properties and a solid evidence-base were selected to capture the
outcomes of interest in a pre-planned, well-defined, structured and
standardised approach. This will potentially increase data-quality,
decrease missing data and provide optimal conditions to investigate
clinically relevant results of TTM for the OHCA-survivors’ neuro-
cognitive function, health and societal participation.
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